EANS-News: AGENNIX AG / Agennix AG Schedules Conference Call on November 18, 2010 to Discuss Third Quarter 2010 Financial Results

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Heidelberg (euro adhoc) - Planegg/Munich (Germany), Princeton, NJ and Houston,
TX, October 28, 2010 - Agennix AG (Frankfurt Stock Exchange: AGX) today
announced that the Company will hold a conference call to discuss financial
results for the third quarter and first nine months of 2010 and to provide a
business update. The results will be published on Thursday, November 18, 2010 in
advance of the conference call. Please note that this date is a change from the
previously announced date of November 4, 2010.

The conference call, which will be conducted in English, will be held on
Thursday, November 18, 2010 at 9 AM ET/3 PM CET.

A live webcast will be available on the Agennix Web site at www.agennix.com. A
replay will be available via the Web site following the live event.

Dial-in numbers for the call are as follows:
Participants from Europe: 0049 (0)69 71044 5598
0044 (0)20 3003 2666
Participants from the U.S.: 1 212 999 6659

Please dial in 10 minutes before the beginning of the call.

About Agennix
Agennix AG is a publicly listed biopharmaceutical company that is focused on the
development of novel therapies that have the potential to substantially improve
the length and quality of life of critically ill patients in areas of major
unmet medical need. The Company´s most advanced program is talactoferrin, an
oral therapy that has demonstrated activity in randomized, double-blind,
placebo-controlled Phase II studies in non-small cell lung cancer, as well as in
severe sepsis. Talactoferrin is currently in Phase III clinical trials in
non-small cell lung cancer, and Agennix plans to develop this program further
for the treatment of severe sepsis. Other clinical development programs include
RGB-286638, a multi-targeted kinase inhibitor in Phase I testing; the oral
platinum-based compound satraplatin; and a topical gel form of talactoferrin for
diabetic foot ulcers. Agennix´s registered seat is in Heidelberg, Germany. The
Company has three sites of operation: Planegg/Munich, Germany; Princeton, New
Jersey and Houston, Texas. For additional information, please visit the Agennix
Web site at www.agennix.com.

This press release contains forward-looking statements, which express the
current beliefs and expectations of the management of Agennix AG. Such
statements are based on current expectations and are subject to risks and
uncertainties, many of which are beyond our control, that could cause future
results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking
statements. Actual results could differ materially depending on a number of
factors, and we caution investors not to place undue reliance on the
forward-looking statements contained in this press release. Forward-looking
statements speak only as of the date on which they are made and Agennix
undertakes no obligation to update these forward-looking statements, even if new
information becomes available in the future.

Agennix? is a trademark of the Agennix group.

Further inquiry note:
Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
[email protected]

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
[email protected]

Additional media contacts for Europe:
MC Services AG
Raimund Gabriel
Phone: +49 (0) 89 210 228 0
[email protected]

Additional investor contact for Europe:
Trout International LLC
Lauren Williams, Vice President
Phone: +44 207 936 9325
[email protected]
end of announcement euro adhoc
--------------------------------------------------------------------------------

company: AGENNIX AG
Im Neuenheimer Feld 515
D-69120 Heidelberg
phone: +49 89 8565 2693
FAX: +49 89 8565 2610
mail: [email protected]
WWW: http://www.agennix.com
sector: Pharmaceuticals
ISIN: DE000A1A6XX4
indexes: CDAX, Prime All Share, Technology All Share
stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin,
Hamburg, Düsseldorf, Hannover, München
language: English

OTS-ORIGINALTEXT PRESSEAUSSENDUNG UNTER AUSSCHLIESSLICHER INHALTLICHER VERANTWORTUNG DES AUSSENDERS - WWW.OTS.AT | CNE

print